No Data
Emerging Markets stock digest: Kaiom rebounds significantly, pluszero surges.
<4599> Stem Inc reduced by 19 to 324. The company's performance for the first quarter of the fiscal year ending July 2025 was announced; there was no business revenue (no business revenue in the same period last year), an operating loss of 0.573 billion yen (compared to an operating loss of 0.491 billion yen), a recurring loss of 0.573 billion yen (compared to a recurring loss of 0.491 billion yen), and a quarterly net loss of 0.56 billion yen (compared to a quarterly net loss of 0.467 billion yen), indicating an expanded deficit. The company's business revenue is primarily composed of milestone income due to development progress, and the proposal.
Hot Stocks Digest (Before Market): Kura Sushi, Synchro Food, Gumi, ETC.
ANYCOLOR <5032>: 2,478 yen (+149 yen) has significantly continued to rise. The previous day, the financial results for the first half of the year were announced, with an operating profit of 6.76 billion yen, a 4.3% increase year-on-year, which fell short of the previous estimate of 7.1 billion yen. However, this is a turnaround from the 2.72 billion yen in the first quarter, representing a 32.8% decrease, resulting in a profit increase. The August to October period is expected to show a substantial profit increase of 65.8%. Supported by the expansion of commerce and events, the operating profit for the November to January period is also forecasted to be between 3.45 and 3.75 billion yen.
Sasumedo---starts providing an integrated venous disease registry.
Buying activity is gradually decreasing in value, leading to a period of consolidation. The construction work for the integrated venous disease registry system, which was advanced based on the basic agreement concluded with Tohoku Universities, has been completed, and provision to companies has commenced. This registry is an integrated system that can simultaneously collect information from patients using multiple Medical Devices, such as new venous stents for symptomatic iliac-femoral venous Outflow obstruction and new thrombectomy catheters for acute deep vein thrombosis. The collected data will be shared with related academic societies and manufacturers.
SASMED --- 1Q sales slightly decreased, revenue from DTx platform business is stable.
Susmed <4263> announced its first quarter results for the fiscal year ending June 2025 (July-September 24). Operating income decreased by 1.4% year-on-year to 0.032 billion yen, operating loss was 0.161 billion yen (compared to a loss of 0.15 billion yen in the same period last year), ordinary loss was 0.163 billion yen (compared to a loss of 0.145 billion yen), and quarterly net loss was 0.163 billion yen (compared to a loss of 0.146 billion yen). There was no recognition of operating income for the DTx product business segment (same as the previous year's same period), and the segment loss was 0.04 billion yen (compared to the same period last year).
Susmed: Presentation of financial results for the 1st quarter of the fiscal year ending 2025/6
Susmed: Summary of financial results for the 1st quarter of the fiscal year ending June 2025 [Japanese GAAP] (unconsolidated)